Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454524 | 0.89 | MEN1 (0.39) | MEN1GAAMAPTCASP1BRCA1 | |
| SCHEMBL13479005 | 0.79 | ALOX5 (0.36) | MAPTKMT2A | |
| SCHEMBL14992419 | 0.76 | ALDH1A1 (0.43) | MAPTKMT2A | |
| SCHEMBL14992417 | 0.76 | ALDH1A1 (0.43) | MAPTKMT2A | |
| SCHEMBL828962 | 0.69 | GAA (0.39) | MEN1GAAMAPTCASP1BRCA1 | |
| SCHEMBL264463 | 0.68 | G6PD (0.38) | GAAMAPTKMT2A | |
| SCHEMBL6153918 | 0.67 | NR5A1 (0.50) | GAAMAPT | |
| SCHEMBL1404270 | 0.61 | G6PD (0.42) | GAAMAPTKMT2A | |
| SCHEMBL1434203 | 0.61 | — | — | |
| SCHEMBL6181011 | 0.60 | CA2 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0910370-B1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING UVEITIS | CENTAUR PHARMACEUTICALS INC (US) | 2004-04-07 | — | — | EP | claimed |
| JP-2000509375-A | — | — | 2000-07-25 | — | — | JP | claimed |
| US-5972977-A | ALPHA-(4-PYRIDYL 1-OXIDE)-N-HYDROCARBYLNITRON USEFUL FOR TREATING EYE INFLAMMATION CONDITION SUCH AS UVEITIS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | claimed |
| EP-0910370-A1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING OCULAR INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1997039751-A1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING OCULAR INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-30 | — | — | WO | claimed |
| EP-0910370-B1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING UVEITIS | CENTAUR PHARMACEUTICALS INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6140356-A | Opthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5972977-A | ALPHA-(4-PYRIDYL 1-OXIDE)-N-HYDROCARBYLNITRON USEFUL FOR TREATING EYE INFLAMMATION CONDITION SUCH AS UVEITIS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0910370-A1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING OCULAR INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997039751-A1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING OCULAR INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-30 | — | — | WO | disclosed |